{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:25Z","timestamp":1740107005225,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00213-023-06407-6","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T20:27:02Z","timestamp":1689625622000},"page":"1911-1920","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison between olanzapine and aripiprazole treatment for 104\u00a0weeks after hospital discharge in schizophrenia spectrum disorders: a multicenter retrospective cohort study in a real-world setting"],"prefix":"10.1007","volume":"240","author":[{"given":"Tomonari","family":"Hosokawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Miyaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusaku","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Washida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Yada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Okahisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soshi","family":"Takao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7371-2821","authenticated-orcid":false,"given":"Manabu","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihito","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"6407_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2165\/00023210-200822070-00002","volume":"22","author":"M \u00c1lvarez-Jim\u00e9nez","year":"2008","unstructured":"\u00c1lvarez-Jim\u00e9nez M, Gonz\u00e1lez-Blanch C, Crespo-Facorro B et al (2008) Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 22:547\u2013562. https:\/\/doi.org\/10.2165\/00023210-200822070-00002","journal-title":"CNS Drugs"},{"key":"6407_CR2","doi-asserted-by":"publisher","first-page":"e94112","DOI":"10.1371\/JOURNAL.PONE.0094112","volume":"9","author":"M Bak","year":"2014","unstructured":"Bak M, Fransen A, Janssen J et al (2014) Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 9:e94112. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0094112","journal-title":"PLoS One"},{"key":"6407_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5455\/MSM.2022.33.25-27","volume":"34","author":"N Be\u0107arevi\u0107","year":"2022","unstructured":"Be\u0107arevi\u0107 N, Softi\u0107 R, Osmanovi\u0107 E (2022) Does the duration of the illness affect the severity of negative symptoms of schizophrenia? Mater Sociomed 34:25\u201327. https:\/\/doi.org\/10.5455\/MSM.2022.33.25-27","journal-title":"Mater Sociomed"},{"key":"6407_CR4","doi-asserted-by":"publisher","unstructured":"Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA BM (2007) Quality of life in schizophrenic patients. Dialogues Clin Neurosci 9:215\u2013226. https:\/\/doi.org\/10.31887\/DCNS.2007.9.2\/JBOBES","DOI":"10.31887\/DCNS.2007.9.2\/JBOBES"},{"key":"6407_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4306\/PI.2012.9.4.354","volume":"9","author":"M Buoli","year":"2012","unstructured":"Buoli M, Caldiroli A, Panza G, Altamura AC (2012) Prominent clinical dimension, duration of illness and treatment response in schizophrenia: a naturalistic study. Psychiatry Investig 9:354\u2013360. https:\/\/doi.org\/10.4306\/PI.2012.9.4.354","journal-title":"Psychiatry Investig"},{"key":"6407_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033291721000180","volume":"24","author":"C Carnovale","year":"2021","unstructured":"Carnovale C, Lucenteforte E, Battini V et al (2021) Association between the glyco-metabolic adverse effects of antipsychotic drugs and their chemical and pharmacological profile: a network meta-analysis and regression. Psychol Med 24:1\u201313. https:\/\/doi.org\/10.1017\/S0033291721000180","journal-title":"Psychol Med"},{"key":"6407_CR7","doi-asserted-by":"publisher","first-page":"CD008016","DOI":"10.1002\/14651858.CD008016.pub3","volume":"8","author":"A Ceraso","year":"2020","unstructured":"Ceraso A, Lin JJ, Schneider-Thoma J et al (2020) Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane database Syst Rev 8:CD008016. https:\/\/doi.org\/10.1002\/14651858.CD008016.pub3","journal-title":"Cochrane database Syst Rev"},{"key":"6407_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-013-0079-5","volume":"27","author":"A Cerovecki","year":"2013","unstructured":"Cerovecki A, Musil R, Klimke A et al (2013) Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 27:545\u2013572. https:\/\/doi.org\/10.1007\/s40263-013-0079-5","journal-title":"CNS Drugs"},{"key":"6407_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00213-006-0564-3","volume":"189","author":"WK Chrzanowski","year":"2006","unstructured":"Chrzanowski WK, Marcus RN, Torbeyns A et al (2006) Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 189:259\u2013266. https:\/\/doi.org\/10.1007\/s00213-006-0564-3","journal-title":"Psychopharmacology (Berl)"},{"key":"6407_CR10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1192\/bjp.146.5.474","volume":"146","author":"DA Curson","year":"1985","unstructured":"Curson DA, Barnes TR, Bamber RW et al (1985) Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine\/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome. Br J Psychiatry 146:474\u2013480. https:\/\/doi.org\/10.1192\/bjp.146.5.474","journal-title":"Br J Psychiatry"},{"key":"6407_CR11","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2147\/NDT.S113099","volume":"13","author":"M Dayabandara","year":"2017","unstructured":"Dayabandara M, Hanwella R, Ratnatunga S et al (2017) Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 13:2231\u20132241. https:\/\/doi.org\/10.2147\/NDT.S113099","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6407_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2013.05.016","volume":"148","author":"R Emsley","year":"2013","unstructured":"Emsley R, Chiliza B, Asmal L (2013) The evidence for illness progression after relapse in schizophrenia. Schizophr Res 148:117\u2013121. https:\/\/doi.org\/10.1016\/j.schres.2013.05.016","journal-title":"Schizophr Res"},{"key":"6407_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-244X-13-50","volume":"13","author":"R Emsley","year":"2013","unstructured":"Emsley R, Chiliza B, Asmal L, Harvey BH (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13:50. https:\/\/doi.org\/10.1186\/1471-244X-13-50","journal-title":"BMC Psychiatry"},{"key":"6407_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/JCP.0b013e31827bfcc1","volume":"33","author":"R Emsley","year":"2013","unstructured":"Emsley R, Oosthuizen P, Koen L et al (2013) Comparison of treatment response in second-episode versus first-episode schizophrenia. J Clin Psychopharmacol 33:80\u201383. https:\/\/doi.org\/10.1097\/JCP.0b013e31827bfcc1","journal-title":"J Clin Psychopharmacol"},{"key":"6407_CR15","doi-asserted-by":"publisher","first-page":"CD005148","DOI":"10.1002\/14651858.CD005148.pub2","volume":"1","author":"G Faulkner","year":"2007","unstructured":"Faulkner G, Cohn T, Remington G (2007) Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 1:CD005148. https:\/\/doi.org\/10.1002\/14651858.CD005148.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"6407_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1001\/jamapsychiatry.2014.2127","volume":"72","author":"TA Furukawa","year":"2015","unstructured":"Furukawa TA, Levine SZ, Tanaka S et al (2015) Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA psychiatry 72:14\u201321. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.2127","journal-title":"JAMA psychiatry"},{"key":"6407_CR17","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","volume":"167","author":"DM Gardner","year":"2010","unstructured":"Gardner DM, Murphy AL, O\u2019Donnell H et al (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167:686\u2013693. https:\/\/doi.org\/10.1176\/appi.ajp.2009.09060802","journal-title":"Am J Psychiatry"},{"key":"6407_CR18","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet (London, England) 394:939\u2013951. https:\/\/doi.org\/10.1016\/S0140-6736(19)31135-3","journal-title":"Lancet (London, England)"},{"key":"6407_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/0019-5545.31617","volume":"48","author":"S Jain","year":"2006","unstructured":"Jain S, Bhargava M, Gautam S (2006) Weight gain with olanzapine: Drug, gender or age? Indian J Psychiatry 48:39\u201342. https:\/\/doi.org\/10.4103\/0019-5545.31617","journal-title":"Indian J Psychiatry"},{"key":"6407_CR20","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H et al (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (London, England) 371:1085\u20131097. https:\/\/doi.org\/10.1016\/S0140-6736(08)60486-9","journal-title":"Lancet (London, England)"},{"key":"6407_CR21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.4088\/jcp.08m04421","volume":"70","author":"JM Kane","year":"2009","unstructured":"Kane JM, Osuntokun O, Kryzhanovskaya LA et al (2009) A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 70:572\u2013581. https:\/\/doi.org\/10.4088\/jcp.08m04421","journal-title":"J Clin Psychiatry"},{"key":"6407_CR22","unstructured":"Kane JM, Leucht S, Carpenter D, Docherty JP (2003) The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64:5\u201319. Retrieved from https:\/\/www.psychiatrist.com\/jcp\/"},{"key":"6407_CR23","unstructured":"Kasper S (1999) First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 60:5\u20139. Retrieved from https:\/\/www.psychiatrist.com\/jcp\/"},{"key":"6407_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/jcp.0b013e31817e63a5","volume":"28","author":"BJ Kinon","year":"2008","unstructured":"Kinon BJ, Volavka J, Stauffer V et al (2008) Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 28:392\u2013400. https:\/\/doi.org\/10.1097\/jcp.0b013e31817e63a5","journal-title":"J Clin Psychopharmacol"},{"key":"6407_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","volume":"177","author":"S Leucht","year":"2020","unstructured":"Leucht S, Crippa A, Siafis S et al (2020) Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Am J Psychiatry 177:342\u2013353. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19010034","journal-title":"Am J Psychiatry"},{"key":"6407_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/archpsyc.1993.01820170047006","volume":"50","author":"J Lieberman","year":"1993","unstructured":"Lieberman J, Jody D, Geisler S et al (1993) Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 50:369\u2013376. https:\/\/doi.org\/10.1001\/archpsyc.1993.01820170047006","journal-title":"Arch Gen Psychiatry"},{"key":"6407_CR27","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223. https:\/\/doi.org\/10.1056\/NEJMoa051688","journal-title":"N Engl J Med"},{"key":"6407_CR28","unstructured":"McQuade RD, Stock E, Marcus R et al. (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65:47\u201356. Retrieved from https:\/\/www.psychiatrist.com\/jcp\/"},{"key":"6407_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4088\/jcp.v69n0214","volume":"69","author":"HY Meltzer","year":"2008","unstructured":"Meltzer HY, Bobo WV, Roy A et al (2008) A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 69:274\u2013285. https:\/\/doi.org\/10.4088\/jcp.v69n0214","journal-title":"J Clin Psychiatry"},{"key":"6407_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00213-019-05352-7","volume":"237","author":"Y Obayashi","year":"2020","unstructured":"Obayashi Y, Mitsui S, Sakamoto S et al (2020) Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole. Psychopharmacology (Berl) 237:167\u2013175. https:\/\/doi.org\/10.1007\/s00213-019-05352-7","journal-title":"Psychopharmacology (Berl)"},{"key":"6407_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L et al (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. The Lancet Psychiatry 7:64\u201377. https:\/\/doi.org\/10.1016\/S2215-0366(19)30416-X","journal-title":"The Lancet Psychiatry"},{"key":"6407_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","volume":"56","author":"D Robinson","year":"1999","unstructured":"Robinson D, Woerner MG, Alvir JMJ et al (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241\u2013247. https:\/\/doi.org\/10.1001\/archpsyc.56.3.241","journal-title":"Arch Gen Psychiatry"},{"key":"6407_CR33","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","volume":"399","author":"J Schneider-Thoma","year":"2022","unstructured":"Schneider-Thoma J, Chalkou K, D\u00f6rries C et al (2022) Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet (London, England) 399:824\u2013836. https:\/\/doi.org\/10.1016\/S0140-6736(21)01997-8","journal-title":"Lancet (London, England)"},{"key":"6407_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.schres.2019.09.013","volume":"215","author":"Y Shimomura","year":"2020","unstructured":"Shimomura Y, Kikuchi Y, Suzuki T et al (2020) Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms. Schizophr Res 215:8\u201316. https:\/\/doi.org\/10.1016\/j.schres.2019.09.013","journal-title":"Schizophr Res"},{"key":"6407_CR35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0193-953X(18)30176-X","volume":"16","author":"RG Stern","year":"1993","unstructured":"Stern RG, Kahn RSDM (1993) Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am 16:313\u2013338. https:\/\/doi.org\/10.1016\/S0193-953X(18)30176-X","journal-title":"Psychiatr Clin North Am"},{"key":"6407_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1192\/bjp.bp.115.177139","volume":"210","author":"SB Teasdale","year":"2017","unstructured":"Teasdale SB, Ward PB, Rosenbaum S et al (2017) Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness. Br J Psychiatry 210:110\u2013118. https:\/\/doi.org\/10.1192\/bjp.bp.115.177139","journal-title":"Br J Psychiatry"},{"key":"6407_CR37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1192\/bjo.2018.17","volume":"4","author":"A Thompson","year":"2018","unstructured":"Thompson A, Winsper C, Marwaha S et al (2018) Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review. BJPsych open 4:215\u2013225. https:\/\/doi.org\/10.1192\/bjo.2018.17","journal-title":"BJPsych open"},{"key":"6407_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.schres.2019.10.015","volume":"225","author":"A \u00dc\u00e7ok","year":"2020","unstructured":"\u00dc\u00e7ok A, Kara \u0130A (2020) Relapse rates following antipsychotic discontinuation in the maintenance phase after first-episode of schizophrenia: Results of a long-term follow-up study. Schizophr Res 225:31\u201338. https:\/\/doi.org\/10.1016\/j.schres.2019.10.015","journal-title":"Schizophr Res"},{"key":"6407_CR39","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.euroneuro.2017.06.011","volume":"27","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Li C, Huhn M et al (2017) How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. Eur Neuropsychopharmacol 27:835\u2013844. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.06.011","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-023-06407-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-023-06407-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-023-06407-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T09:03:18Z","timestamp":1693472598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-023-06407-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6407"],"URL":"https:\/\/doi.org\/10.1007\/s00213-023-06407-6","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"type":"print","value":"0033-3158"},{"type":"electronic","value":"1432-2072"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"assertion":[{"value":"24 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.Y. has received unrestricted research funding from Daiichi Sankyo, Eisai, Pfizer, Otsuka, Astellas, and Merck Sharp & Dohme, which was deposited into research accounts at Okayama University. N.Y. has received honoraria for his participation as a speaker at educational events from UCB Japan, Tsumura, Pfizer, Dainippon-Sumitomo, Daiichi-Sankyo, Merck Sharp & Dohme, Pfizer, Eisai, Meiji-Seika, and Mochida.M.T. has received honoraria for his participation as a speaker at education events sponsored by Daiichi Sankyo, Takeda, Tsumura, Otsuka, and Dainippon Sumitomo.Y. Yada has received honoraria for speaking at educational events sponsored by Novartis, Otsuka, and Dainippon Sumitomo.S.S. has received unrestricted research funding from Eli Lilly, which was deposited into research accounts at Okayama University Hospital. S.S. has received honoraria for his participation as a speaker at an educational event sponsored by Otsuka and Meiji-Seika.Y.K. has received honoraria for his participation as a speaker at educational events sponsored by Novartis and Dainippon Sumitomo.T. Hosokawa, C.M., Y. Yoshimura, Y.O., K. Washida, S.T., A.N., T. Harada, and T.T. report no additional financial or other relationship relevant to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}